⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
RNTX News
Rein Therapeutics, Inc. Common Stock
Cell Line Development Market - Global Forecast 2026-2032 | AI, Automation, and Biologics Demand Drive 10.02% CAGR, Creating a USD 23.24 Billion Opportunity by 2032
globenewswire.com
CDNS
CRL
COO
DHR
ES
FGEN
GNS
LNZA
MRK
NOV
RNTX
SCL
SNPS
TMO
Coronary Artery Disease Clinical Trial Space Intensifies with 20+ Companies in Active Development | DelveInsight
globenewswire.com
CYTK
NVO
BCDA
AZN
MESO
GEHC
BSX
MDT
ABT
LIVN
OSCR
EL
BMY
ARE
AVT
RNTX
Form 8-K
sec.gov
RNTX
Rein Therapeutics to Present Late-Breaking Poster at the European Respiratory Society (ERS) 2026 Congress
globenewswire.com
RNTX
Rein Therapeutics to Present at Upcoming September Investor Conferences
globenewswire.com
RNTX
Form 8-K
sec.gov
RNTX
Rein Therapeutics Receives U.S. FDA Fast Track Designation for LTI-03 in Idiopathic Pulmonary Fibrosis
globenewswire.com
RNTX
Rein Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
globenewswire.com
RNTX
Rein Therapeutics Announces Publication of Landmark LTI-03 Clinical Data in Nature Communications
globenewswire.com
RNTX
Form 8-K
sec.gov
RNTX